Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review

Abstract

A 2008 review by our group concluded that the risk of neuropsychiatric adverse events (NPAEs) in influenza patients was not increased by oseltamivir exposure, and did not identify any mechanism by which oseltamivir or its metabolites could cause or worsen such events. The current article reviews new information on this topic. Between September 16, 2007 and May 15, 2010, 1,805 spontaneously-reported NPAEs were identified in 1,330 patients receiving oseltamivir: 767 (42.5%) from Japan, 296 (16.4%) from the USA, and 742 (41.1%) from other countries. NPAEs were more common in children: 1,072 (59.4%) events were in those aged ≤16 years. NPAEs often occurred within 48 h of treatment initiation (953 events; 52.8%). Nearly half of the events were serious in nature (838; 46.4%). The three largest categories of events were abnormal behavior (457 events, 25.3%), miscellaneous psychiatric events (370; 20.5%), and delusions/perceptual disturbances (316 events, 17.5%). A total of 1,545 events (85.6%) in eight different categories were considered to be delirium or delirium-like. Twenty-eight suicide-related events were reported. A US healthcare claims database analysis showed that the risk of NPAEs in 7,798 oseltamivir-treated patients was no higher than that in 10,411 patients not on antivirals, but a study on oseltamivir and abnormal behavior in Japan was less conclusive. NPAE frequency in oseltamivir-exposed Japanese and Taiwanese children with influenza was the same as in unexposed children. New analysis of the UK General Practice Research Database showed that the relative adjusted risk of NPAEs in influenza patients was 2.18-times higher than in the general population. Other epidemiology studies report frequent occurrence of encephalitis and similar disorders in influenza patients independently of oseltamivir exposure. The new data support the findings of the original assessment. Evidence suggests that influenza-related encephalopathies are caused by influenza-induced inflammatory responses, but more work is needed to confirm the underlying mechanisms.

Supplementary material is available on SpringerLink.com.

References

  1. 1.

    Toovey S, Rayner C, Prinssen E, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf. 2008;31:1097–114.

    PubMed  CAS  Google Scholar 

  2. 2.

    Kasai T, Togashi T, Morishima T. Encephalopathy associated with influenza epidemics. Lancet. 2000;355:1558–9.

    PubMed  CAS  Google Scholar 

  3. 3.

    Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect Dis. 2002;35:512–7.

    PubMed  Google Scholar 

  4. 4.

    Okabe N, Yamashita K, Taniguchi K, Inouye S. Influenza surveillance system of Japan and acute encephalitis and encephalopathy in the influenza season. Pediatr Int. 2000;42:187–91.

    PubMed  CAS  Google Scholar 

  5. 5.

    Food and Drug Administration (FDA). Meeting of the FDA Pediatric Advisory Committee. November 16, 2006. Available at: http://www.fda.gov/OHRMS/DOCKETS/ac/oc06.htm. Accessed Sep 10 2012

  6. 6.

    Donner B, Bader-Weder S, Schwarz R, Peng MM, Smith JR, Niranjan V. Safety profile of oseltamivir during the 2009 influenza pandemic. Pharmacoepidemiol Drug Saf. 2011;20:532–43.

    PubMed  Google Scholar 

  7. 7.

    Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract. 2009;63:596–605.

    PubMed  CAS  Google Scholar 

  8. 8.

    Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health. 2009;21:79–89.

    PubMed  Google Scholar 

  9. 9.

    Hirota Y. Survey research on the emergence of influenza-associated symptoms. 2007/2008 research subteam report. 2009. Tokyo: MHLW Scientific Research Fund.

    Google Scholar 

  10. 10.

    Yorifuji T, Suzuki E, Tsuda T. Oseltamivir and abnormal behaviors: true or not? Epidemiology. 2009;20:619–21.

    PubMed  Google Scholar 

  11. 11.

    Peng MM, Robinson NJ. Oseltamivir and abnormal behavior. Epidemiology. 2010;21:915–6.

    PubMed  Google Scholar 

  12. 12.

    Kimberlin DW, Shalabi M, Abzug MJ, et al. Safety of oseltamivir compared with the adamantanes in children less than 12 months of age. Pediatr Infect Dis J. 2010;29:195–8.

    PubMed  Google Scholar 

  13. 13.

    Hama R. Fatal neuropsychiatric adverse reactions to oseltamivir: case series and overview of causal relationship. Int J Risk Saf Med. 2008;20:5–36.

    Google Scholar 

  14. 14.

    Huang YC, Li WC, Tsao KC, et al. Influenza-associated central nervous system dysfunction in Taiwanese children: clinical characteristics and outcomes with and without administration of oseltamivir. Pediatr Infect Dis J. 2009;28:647–8.

    PubMed  Google Scholar 

  15. 15.

    Tanabe T, Hara K, Nakajima M, Shimakawa S, Tamai H. Oseltamivir treatment for children showing abnormal behavior during influenza virus infection. Brain Dev. 2010;32:440–4.

    PubMed  Google Scholar 

  16. 16.

    Takanashi J, Tada H, Kuroki H, Barkovich AJ. Delirious behavior in influenza is associated with a reversible splenial lesion. Brain Dev. 2009;31:423–6.

    PubMed  Google Scholar 

  17. 17.

    Baltagi SA, Shoykhet M, Felmet K, Kochanek PM, Bell MJ. Neurological sequelae of 2009 influenza A (H1N1) in children: a case series observed during a pandemic. Pediatr Crit Care Med. 2010;11:179–84.

    PubMed  Google Scholar 

  18. 18.

    Rellosa N, Bloch KC, Shane AL, Debiasi RL. Neurologic manifestations of pediatric novel H1N1 influenza infection. Pediatr Infect Dis J. 2011;30:165–7.

    PubMed  Google Scholar 

  19. 19.

    Tan K, Prerna A, Leo YS. Surveillance of H1N1-related neurological complications. Lancet Neurol. 2010;9:142–3.

    PubMed  Google Scholar 

  20. 20.

    Wiwanitkit V. Swine flu encephalitis: a comment on the first case in Thailand. J Neurol Sci. 2009;26:518–9.

    Google Scholar 

  21. 21.

    Calitri C, Gabiano C, Garazzino S, et al. Clinical features of hospitalised children with 2009 H1N1 influenza virus infection. Eur J Pediatr. 2010;169:1511–5.

    PubMed  Google Scholar 

  22. 22.

    Centers for Disease Control and Prevention (CDC). Neurologic complications associated with novel influenza A (H1N1) virus infection in children — Dallas, Texas, May 2009. MMWR Morb Mortal Wkly Rep. 2009;58:773–8.

    Google Scholar 

  23. 23.

    Chen YC, Lo CP, Chang TP. Novel influenza A (H1N1)-associated encephalopathy/encephalitis with severe neurological sequelae and unique image features — A case report. J Neurol Sci. 2010;298:110–3.

    PubMed  Google Scholar 

  24. 24.

    Citerio G, Sala F, Patruno A, et al. Influenza A (H1N1) encephalitis with severe intracranial hypertension. Minerva Anestesiol. 2010;76:459–62.

    PubMed  CAS  Google Scholar 

  25. 25.

    German-Diaz M, Pavo-Garcia R, Diaz-Diaz J, Giangaspro-Corradi E, Negreira-Cepeda S. Adolescent with neuropsychiatric symptoms associated with novel influenza A (H1N1) virus infection. Pediatr Infect Dis J. 2010;29:570–1.

    PubMed  Google Scholar 

  26. 26.

    Gonzalez BE, Brust DG. Novel influenza A (H1N1) presenting as an acute febrile encephalopathy in a mother and daughter. Clin Infect Dis. 2009;49:1966–7.

    PubMed  Google Scholar 

  27. 27.

    Haktanir A. MR imaging in novel influenza A(H1N1)-associated meningoencephalitis. AJNR Am J Neuroradiol. 2010;31:394–5.

    PubMed  CAS  Google Scholar 

  28. 28.

    Kedia S, Stroud B, Parsons J, et al. Pediatric neurological complications of 2009 pandemic influenza A (H1N1). Arch Neurol. 2011;68:455–62.

    PubMed  Google Scholar 

  29. 29.

    Kwong KL, Hiu H, Hui CM, Que TL. A tragic case of flu. HK J Paediatr. 2007;12:199–201.

    Google Scholar 

  30. 30.

    Lee N, Wong CK, Chan PK, et al. Acute encephalopathy associated with influenza A infection in adults. Emerg Infect Dis. 2010;16:139–42.

    PubMed  CAS  Google Scholar 

  31. 31.

    Li X, Du Y. Neurologic complications associated with novel influenza A (H1N1) virus infection in Nanchong, Chengdu, November 2009. J Exp Clin Med. 2010;2:254–6.

    Google Scholar 

  32. 32.

    Mariotti P, Iorio R, Frisullo G, et al. Acute necrotizing encephalopathy during novel influenza A (H1N1) virus infection. Ann Neurol. 2010;68:111–4.

    PubMed  Google Scholar 

  33. 33.

    Martin A, Reade EP. Acute necrotizing encephalopathy progressing to brain death in a pediatric patient with novel influenza A (H1N1) infection. Clin Infect Dis. 2010;50:e50–e52.

    PubMed  Google Scholar 

  34. 34.

    Noriega LM, Verdugo RJ, Araos R, et al. Pandemic influenza A (H1N1) 2009 with neurological manifestations, a case series. Influenza Other Respi Viruses. 2010;4:117–20.

    PubMed  Google Scholar 

  35. 35.

    O’Leary MF, Chappell JD, Stratton CW, et al. Complex febrile seizures followed by complete recovery in an infant with high-titer 2009 pandemic influenza A (H1N1) virus infection. J Clin Microbiol. 2010;48:3803–5.

    PubMed  Google Scholar 

  36. 36.

    Ormitti F, Ventura E, Summa A, Picetti E, Crisi G. Acute necrotizing encephalopathy in a child during the 2009 influenza A(H1N1) pandemia: MR imaging in diagnosis and follow-up. AJNR Am J Neuroradiol. 2010;31:396–400.

    PubMed  CAS  Google Scholar 

  37. 37.

    Samuel N, Attias O, Tatour S, Brik R. Novel influenza A (H1N1) and acute encephalitis in a child. Isr Med Assoc J. 2010;12:446–7.

    PubMed  Google Scholar 

  38. 38.

    Tada H, Takanashi JI, Terada H, Tajima K. Severe form of acute influenza encephalopathy with biphasic seizures and late reduced diffusion. Neuropediatrics. 2008;39:134–6.

    PubMed  CAS  Google Scholar 

  39. 39.

    Webster RI, Hazelton B, Suleiman J, et al. Severe encephalopathy with swine origin influenza A H1N1 infection in childhood: case reports. Neurology. 2010;74:1077–8.

    PubMed  CAS  Google Scholar 

  40. 40.

    Yamashita S, Kouzaki Y, Kawano R, Tokunaga M, Uchino M. Acute ophthalmoparesis accompanied with influenza A infection. Intern Med. 2008;47:1627–9.

    PubMed  Google Scholar 

  41. 41.

    Yildizdas D, Kendirli T, Arslankoylu AE, et al. Neurological complications of pandemic influenza (H1N1) in children. Eur J Pediatr. 2011;170:779–88.

    PubMed  Google Scholar 

  42. 42.

    Akins PT, Belko J, Uyeki TM, et al. H1N1 encephalitis with malignant edema and review of neurologic complications from influenza. Neurocrit Care. 2010;13:396–406.

    PubMed  Google Scholar 

  43. 43.

    Choi SY, Jang SH, Kim JO, et al. Novel swine-origin influenza A (H1N1) viral encephalitis. Yonsei Med J. 2010;51:291–2.

    PubMed  Google Scholar 

  44. 44.

    Costiniuk CT, Le SN, Sell E, et al. Miller Fisher syndrome in a toddler with influenza A (pH1N1) infection. J Child Neurol. 2011;26:385–8.

    PubMed  Google Scholar 

  45. 45.

    Gadoth A, Aizenstein O, Mosek A. Influenza A/H1N1 encephalitis. Neurology. 2010;75:666–7.

    PubMed  CAS  Google Scholar 

  46. 46.

    Kimura E, Okamoto S, Uchida Y, et al. A reversible lesion of the corpus callosum splenium with adult influenza-associated encephalitis/encephalopathy: a case report. J Med Case Reports. 2008;2:220.

    Google Scholar 

  47. 47.

    Sanchez-Torrent L, Trivino-Rodriguez M, Suero-Toledano P, et al. Novel influenza A (H1N1) encephalitis in a 3-month-old infant. Infection. 2010;38:227–9.

    PubMed  CAS  Google Scholar 

  48. 48.

    Fugate JE, Lam EM, Rabinstein AA, Wijdicks EF. Acute hemorrhagic leukoencephalitis and hypoxic brain injury associated with H1N1 influenza. Arch Neurol. 2010;67:756–8.

    PubMed  Google Scholar 

  49. 49.

    Gonzalez-Duarte A, Magana ZL, Cantu BC, Garcia-Ramos G. Hypothalamic abnormalities and Parkinsonism associated with H1N1 influenza infection. J Neuroinflammation. 2010;7:47.

    PubMed  Google Scholar 

  50. 50.

    Data on file. Basel: Roche; 2010.

  51. 51.

    Okabe N. Research on Abnormal Behaviour Accompanying Influenza — Report of the 2008–2009 season. Available at: http://www.mhlw.go.jp/shingi/2009/06/dl/s0603-6b.pdf. Accessed 23 Sep 2012

  52. 52.

    Fowler A, Stodberg T, Eriksson M, Wickstrom R. Childhood encephalitis in Sweden: etiology, clinical presentation and outcome. Eur J Paediatr Neurol. 2008;12:484–90.

    PubMed  CAS  Google Scholar 

  53. 53.

    Hjalmarsson A, Blomqvist P, Brytting M, Linde A, Skoldenberg B. Encephalitis after influenza in Sweden 1987-1998: a rare complication of a common infection. Eur Neurol. 2009;61:289–94.

    PubMed  Google Scholar 

  54. 54.

    Amin R, Ford-Jones E, Richardson SE, et al. Acute childhood encephalitis and encephalopathy associated with influenza: a prospective 11-year review. Pediatr Infect Dis J. 2008;27:390–5.

    PubMed  Google Scholar 

  55. 55.

    Ekstrand JJ, Herbener A, Rawlings J, et al. Heightened neurologic complications in children with pandemic H1N1 influenza. Ann Neurol. 2010;68:762–6.

    PubMed  Google Scholar 

  56. 56.

    Fukumoto Y, Okumura A, Hayakawa F, et al. Serum levels of cytokines and EEG findings in children with influenza associated with mild neurological complications. Brain Dev. 2007;29:425–30.

    PubMed  Google Scholar 

  57. 57.

    Li WC, Shih SR, Huang YC, et al. Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. J Clin Virol. 2008;42:45–51.

    PubMed  Google Scholar 

  58. 58.

    Chung B, Wong V. Relationship between five common viruses and febrile seizure in children. Arch Dis Child. 2007;92:593.

    Google Scholar 

  59. 59.

    Chung BH, Tsang AM, Wong VC. Neurologic complications in children hospitalized with influenza: comparison between USA and Hong Kong. J Pediatr. 2007;151:e17–8.

    PubMed  Google Scholar 

  60. 60.

    Kwong KL, Lung D, Wong SN, Que TL, Kwong NS. Influenza-related hospitalisations in children. J Paediatr Child Health. 2009;45:660–4.

    PubMed  Google Scholar 

  61. 61.

    Hon KL, Leung E, Tang J, et al. Premorbid factors and outcome associated with respiratory virus infections in a pediatric intensive care unit. Pediatr Pulmonol. 2008;43:275–80.

    PubMed  Google Scholar 

  62. 62.

    Louie JK, Gavali S, Acosta M, et al. Children hospitalized with 2009 novel influenza A(H1N1) in California. Arch Pediatr Adolesc Med. 2010;164:1023–31.

    PubMed  Google Scholar 

  63. 63.

    Parakh A, Kumar A, Kumar V, Dutta AK, Khare S. Pediatric hospitalizations associated with 2009 pandemic influenza A (H1N1): an experience from a tertiary care center in North India. Indian J Pediatr. 2010;77:981–5.

    PubMed  Google Scholar 

  64. 64.

    Stein M, Tasher D, Glikman D, et al. Hospitalization of children with influenza A(H1N1) virus in Israel during the 2009 outbreak in Israel: a multicenter survey. Arch Pediatr Adolesc Med. 2010;164:1015–22.

    PubMed  Google Scholar 

  65. 65.

    Zheng Y, He Y, Deng J, et al. Hospitalized children with 2009 influenza a (H1N1) infection in Shenzhen, China, November–December 2009. Pediatr Pulmonol. 2010; Oct 20. [Epub ahead of print.]

  66. 66.

    Shin SY, Kim JH, Kim HS, et al. Clinical characteristics of Korean pediatric patients critically ill with influenza A (H1N1) virus. Pediatr Pulmonol. 2010;45:1014–20.

    PubMed  Google Scholar 

  67. 67.

    Zhao C, Gan Y, Sun J. Radiographic study of severe Influenza-A (H1N1) disease in children. Eur J Radiol 2011;79:447–51.

    PubMed  Google Scholar 

  68. 68.

    Wada T, Morishima T, Okumura A, et al. Differences in clinical manifestations of influenza-associated encephalopathy by age. Microbiol Immunol. 2009;53:83–8.

    PubMed  CAS  Google Scholar 

  69. 69.

    Nagao T, Morishima T, Kimura H, et al. Prognostic factors in influenza-associated encephalopathy. Pediatr Infect Dis J. 2008;27:384–9.

    PubMed  Google Scholar 

  70. 70.

    Wang CC, Chen PY, Wang JD, et al. Clinical and laboratory analysis of influenza B infection in children in Taichung, Taiwan during the 2006–2007 flu season. Pediatr Neonatol. 2009;50:54–8.

    PubMed  Google Scholar 

  71. 71.

    Terada K, Kawai Y, Monju A, Wakabayashi T, Ouchi K. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J. 2008;27:88–9.

    PubMed  Google Scholar 

  72. 72.

    Takayanagi M, Umehara N, Watanabe H, et al. Acute encephalopathy associated with influenza C virus infection. Pediatr Infect Dis J. 2009;28:554.

    PubMed  Google Scholar 

  73. 73.

    Okumura A, Abe S, Kidokoro H, Mizuguchi M. Acute necrotizing encephalopathy: a comparison between influenza and non-influenza cases. Microbiol Immunol. 2009;53:277–80.

    PubMed  CAS  Google Scholar 

  74. 74.

    Gika AD, Rich P, Gupta S, Neilson DE, Clarke A. Recurrent acute necrotizing encephalopathy following influenza A in a genetically predisposed family. Dev Med Child Neurol. 2010;52:99–102.

    PubMed  Google Scholar 

  75. 75.

    Lyon JB, Remigio C, Milligan T, Deline C. Acute necrotizing encephalopathy in a child with H1N1 influenza infection. Pediatr Radiol. 2010;40:200–5.

    PubMed  Google Scholar 

  76. 76.

    Ng WF, Chiu SC, Lam DS, et al. A 7-year-old boy dying of acute encephalopathy. Brain Pathol. 2010;20:261–4.

    PubMed  Google Scholar 

  77. 77.

    Troedson C, Gill D, Dale RC. Emergence of acute necrotising encephalopathy in Australia. J Paediatr Child Health. 2008;44:599–601.

    PubMed  Google Scholar 

  78. 78.

    Neilson DE, Adams MD, Orr CM, et al. Infection-triggered familial or recurrent cases of acute necrotizing encephalopathy caused by mutations in a component of the nuclear pore, RANBP2. Am J Hum Genet. 2009;84:44–51.

    PubMed  CAS  Google Scholar 

  79. 79.

    Bartynski WS, Upadhyaya AR, Petropoulou KA, Boardman JF. Influenza A encephalopathy, cerebral vasculopathy, and posterior reversible encephalopathy syndrome: combined occurrence in a 3-year-old child. AJNR Am J Neuroradiol. 2010;31:1443–6.

    PubMed  CAS  Google Scholar 

  80. 80.

    Bartynski WS, Upadhyaya AR, Boardman JF. Posterior reversible encephalopathy syndrome and cerebral vasculopathy associated with influenza A infection: report of a case and review of the literature. J Comput Assist Tomogr. 2009;33:917–22.

    PubMed  Google Scholar 

  81. 81.

    Henry J, Smeyne RJ, Jang H, Miller B, Okun MS. Parkinsonism and neurological manifestations of influenza throughout the 20th and 21st centuries. Parkinsonism Relat Disord. 2010;16:566–71.

    PubMed  Google Scholar 

  82. 82.

    Toovey S, Jick SS, Meier CR. Parkinson’s disease or Parkinson symptoms following seasonal influenza. Influenza Other Respi Viruses. 2011;5:328–33.

    PubMed  Google Scholar 

  83. 83.

    Hoffmann G, Funk C, Fowler S, et al. Nonclinical pharmacokinetics of oseltamivir and oseltamivir carboxylate in the central nervous system. Antimicrob Agents Chemother. 2009;53:4753–61.

    PubMed  CAS  Google Scholar 

  84. 84.

    Hatori A, Arai T, Yanamoto K, et al. Biodistribution and metabolism of the anti-influenza drug [11C] oseltamivir and its active metabolite [11C]Ro 64-0802 in mice. Nucl Med Biol. 2009;36:47–55.

    PubMed  CAS  Google Scholar 

  85. 85.

    Jhee SS, Yen M, Ereshefsky L, et al. Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers. Antimicrob Agents Chemother. 2008;52:3687–93.

    PubMed  CAS  Google Scholar 

  86. 86.

    Ose A, Ito M, Kusuhara H, et al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos. 2009;37:315–21.

    PubMed  CAS  Google Scholar 

  87. 87.

    Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem. 2011;117:333–45.

    PubMed  CAS  Google Scholar 

  88. 88.

    Oshima S, Nemoto E, Kuramochi M, Saitoh Y, Kobayashi D. Penetration of oseltamivir and its active metabolite into the brain after lipopolysaccharide-induced inflammation in mice. J Pharm Pharmacol. 2009;61:1397–400.

    PubMed  CAS  Google Scholar 

  89. 89.

    Lindemann L, Jacobsen H, Schuhbauer D, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu®) and active metabolite. Eur J Pharmacol. 2010;628:6–10.

    PubMed  CAS  Google Scholar 

  90. 90.

    Izumi Y, Tokuda K, O’Dell KA, Zorumski CF, Narahashi T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett. 2007;426:54–8.

    PubMed  CAS  Google Scholar 

  91. 91.

    Knoflach F, Trube G, Buisson B, Steidl-Armougom E, Prinssen P, Lindemann L. Evaluation of pharmacological activities of oseltamivir on paired-pulse inhibition in the CA1 region of adult rat hippocampus. p. 822.18. Available at: http://www.sfn.org/skins/main/pdf/abstracts/am2009/poster_presentations/PosterPresentation_WedPM.pdf. Accessed Sep 10 2012

  92. 92.

    Usami A, Sasaki T, Satoh N, et al. Oseltamivir enhances hippocampal network synchronization. J Pharmacol Sci. 2008;106:659–62.

    PubMed  CAS  Google Scholar 

  93. 93.

    Satoh K, Nonaka R, Ogata A, Nakae D, Uehara S. Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain. Biol Pharm Bull. 2007;30:1816–8.

    PubMed  CAS  Google Scholar 

  94. 94.

    Data on file. Basel: Roche; 1998.

  95. 95.

    Izumi Y, Tokuda K, O’Dell K, Zorumski C, Narahashi T. Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants. Hum Exp Toxicol. 2008;27:911–7.

    PubMed  CAS  Google Scholar 

  96. 96.

    Uchimura N, Kuwahara H, Kumagai Y, et al. Absence of adverse effects of oseltamivir on sleep: a double-blind, randomized study in healthy volunteers in Japan. Basic Clin Pharmacol Toxicol. 2011;109:309–14.

    PubMed  CAS  Google Scholar 

  97. 97.

    Doucette KE, Aoki FY. Oseltamivir: a clinical and pharmacological perspective. Expert Opin Pharmacother. 2001;2:1671–83.

    PubMed  CAS  Google Scholar 

  98. 98.

    He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999;37:471–84.

    PubMed  CAS  Google Scholar 

  99. 99.

    Shi D, Yang J, Yang D, et al. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther. 2006;319:1477–84.

    PubMed  CAS  Google Scholar 

  100. 100.

    Zhu HJ, Markowitz JS. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos. 2009;37:264–7.

    PubMed  CAS  Google Scholar 

  101. 101.

    Yang D, Pearce RE, Wang X, et al. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol. 2009;77:238–47.

    PubMed  CAS  Google Scholar 

  102. 102.

    Zhu HJ, Appel DI, Jiang Y, Markowitz JS. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos. 2009;37:1819–25.

    PubMed  CAS  Google Scholar 

  103. 103.

    Oo C, Barrett J, Hill G, et al. Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children. Paediatr Drugs. 2001;3:229–36.

    PubMed  CAS  Google Scholar 

  104. 104.

    Acosta EP, Jester P, Gal P, et al. Oseltamivir dosing for influenza infection in premature neonates. J Infect Dis. 2010;202:563–6.

    PubMed  CAS  Google Scholar 

  105. 105.

    Aiba H, Mochizuki M, Kimura M, Hojo H. Predictive value of serum interleukin-6 level in influenza virus-associated encephalopathy. Neurology. 2001;57:295–9.

    PubMed  CAS  Google Scholar 

  106. 106.

    Ichiyama T, Isumi H, Ozawa H, et al. Cerebrospinal fluid and serum levels of cytokines and soluble tumor necrosis factor receptor in influenza virus-associated encephalopathy. Scand J Infect Dis. 2003;35:59–61.

    PubMed  CAS  Google Scholar 

  107. 107.

    Cisse Y, Wang S, Inoue I, Kido H. Rat model of influenza-associated encephalopathy (IAE): studies of electroencephalogram (EEG) in vivo. Neuroscience. 2010;165:1127–37.

    PubMed  CAS  Google Scholar 

  108. 108.

    Tanaka T, Sunden Y, Sakoda Y, et al. Lipopolysaccharide treatment and inoculation of influenza A virus results in influenza virus-associated encephalopathy-like changes in neonatal mice. J Neurovirol. 2010;16:125–32.

    PubMed  CAS  Google Scholar 

  109. 109.

    Riazi K, Galic MA, Kuzmiski JB, et al. Microglial activation and TNFalpha production mediate altered CNS excitability following peripheral inflammation. Proc Natl Acad Sci USA. 2008;105:17151–6.

    PubMed  CAS  Google Scholar 

  110. 110.

    Tsuge M, Yasui K, Ichiyawa T, et al. Increase of tumor necrosis factor-alpha in the blood induces early activation of matrix metalloproteinase-9 in the brain. Microbiol Immunol. 2010;54:417–24.

    PubMed  CAS  Google Scholar 

  111. 111.

    Serrats J, Schiltz JC, Garcia-Bueno B, et al. Dual roles for perivascular macrophages in immune-tobrain signaling. Neuron. 2010;65:94–106.

    PubMed  CAS  Google Scholar 

  112. 112.

    Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009;73:768–74.

    PubMed  CAS  Google Scholar 

  113. 113.

    Steinman L. Nuanced roles of cytokines in three major human brain disorders. J Clin Invest. 2008;118:3557–63.

    PubMed  CAS  Google Scholar 

  114. 114.

    Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.

    PubMed  CAS  Google Scholar 

  115. 115.

    Bentivoglio M, Kristensson K. Neural-immune interactions in disorders of sleep-wakefulness organization. Trends Neurosci. 2007;30:645–52.

    PubMed  CAS  Google Scholar 

  116. 116.

    Matsubara K, Kodera M, Nigami H, Yura K, Fukaya T. Reversible splenial lesion in influenza virus encephalopathy. Pediatr Neurol. 2007;37:431–4.

    PubMed  Google Scholar 

  117. 117.

    Fluss J, Ferey S, Menache-Starobinski C, et al. Mild influenza-associated encephalopathy/encephalitis with a reversible splenial lesion in a Caucasian child with additional cerebellar features. Eur J Paediatr Neurol. 2010;14:97–100.

    PubMed  Google Scholar 

  118. 118.

    Ganapathy S, Ey EH, Wolfson BJ, Khan N. Transient isolated lesion of the splenium associated with clinically mild influenza encephalitis. Pediatr Radiol. 2008;38:1243–5.

    PubMed  Google Scholar 

  119. 119.

    Iwata A, Matsubara K, Nigami H, Kamimura K, Fukaya T. Reversible splenial lesion associated with novel influenza A (H1N1) viral infection. Pediatr Neurol. 2010;42:447–50.

    PubMed  Google Scholar 

  120. 120.

    Tsuji M, Yoshida T, Miyakoshi C, Haruta T. Is a reversible splenial lesion a sign of encephalopathy? Pediatr Neurol. 2009;41:143–5.

    PubMed  Google Scholar 

  121. 121.

    Kotan D. Widespread subarachnoidal pneumocephalus development as a complication of influenza: a case report. Arch Med Sci. 2008;4:471–3.

    Google Scholar 

  122. 122.

    Sumikoshi M, Hashimoto K, Kawasaki Y, et al. Human influenza virus infection and apoptosis induction in human vascular endothelial cells. J Med Virol. 2008;80:1072–8.

    PubMed  CAS  Google Scholar 

  123. 123.

    Wang G, Zhang J, Li W, et al. Apoptosis and proinflammatory cytokine responses of primary mouse microglia and astrocytes induced by human H1N1 and avian H5N1 influenza viruses. Cell Mol Immunol. 2008;5:113–20.

    PubMed  CAS  Google Scholar 

  124. 124.

    Kawada J, Kimura H, Ito Y, et al. Systemic cytokine responses in patients with influenza-associated encephalopathy. J Infect Dis. 2003;188:690–8.

    PubMed  CAS  Google Scholar 

  125. 125.

    van Zeijl JH, Bakkers J, Wilbrink B, et al. Influenza-associated encephalopathy: no evidence for neuroinvasion by influenza virus nor for reactivation of human herpesvirus 6 or 7. Clin Infect Dis. 2005;40:483–5.

    PubMed  Google Scholar 

  126. 126.

    Morishima T. Influenza-associated encephalopathy. No To Shinkei. 2006;58:561–9. In Japanese.

    PubMed  Google Scholar 

  127. 127.

    Shinohara M, Saitoh M, Takanashi JI, et al. Carnitine palmitoyl transferase II polymorphism is associated with multiple syndromes of acute encephalopathy with various infectious diseases. Brain Dev. 2011;33:512–7.

    PubMed  Google Scholar 

  128. 128.

    Yao D, Mizuguchi H, Yamaguchi M, et al. Thermal instability of compound variants of carnitine palmitoyltransferase II and impaired mitochondrial fuel utilization in influenza-associated encephalopathy. Hum Mutat. 2008;29:718–27.

    PubMed  CAS  Google Scholar 

  129. 129.

    Chen Y, Mizuguchi H, Yao D, et al. Thermolabile phenotype of carnitine palmitoyltransferase II variations as a predisposing factor for influenza-associated encephalopathy. FEBS Lett. 2005;579:2040–4.

    PubMed  CAS  Google Scholar 

  130. 130.

    Hosoya M, Kawasaki Y, Katayose M, et al. Prognostic predictive values of serum cytochrome c, cytokines, and other laboratory measurements in acute encephalopathy with multiple organ failure. Arch Dis Child. 2006;91:469–72.

    PubMed  CAS  Google Scholar 

  131. 131.

    Purevsuren J, Hasegawa Y, Kobayashi H, Endo M, Yamaguchi S. Urinary organic metabolite screening of children with influenza-associated encephalopathy for inborn errors of metabolism using GC/MS. Brain Dev. 2008;30:520–6.

    PubMed  Google Scholar 

  132. 132.

    Okamoto E. Incidence of injuries after influenza using health insurance claims. Jpn J Pharmacoepidemiol. 2009;21:50–1.

    Google Scholar 

  133. 133.

    Berger JR, Houff SA. Neurological infections: the year of PML and influenza. Lancet Neurol. 2010;9:14–7.

    PubMed  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Stephen Toovey.

Additional information

To view enhanced content go to www.advancesintherapy.com

This article is published with open access at Springerlink.com

Electronic supplementary material

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Toovey, S., Prinssen, E.P., Rayner, C.R. et al. Post-Marketing Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir: An Updated Review. Adv Therapy 29, 826–848 (2012). https://doi.org/10.1007/s12325-012-0050-8

Download citation

Keywords

  • Adverse events
  • Central nervous system
  • Influenza
  • Neuropsychiatric
  • Oseltamivir
  • Safety
  • Tolerability